Home » Topics » Disease categories and therapies » Respiratory

Respiratory
RSS

Schering-Plough to market pranlukast in Latin America

Dec. 22, 2000

Anti-IL-9 antibody collaboration terminated by Genentech

Dec. 22, 2000

PDE7 inhibitors and their use presented by Darwin Discovery

Dec. 19, 2000

R&D at Texas Biotechnology leads to identification of new integrin inhibitors

Dec. 19, 2000

Treatments for inflammatory disorders in development at Aventis inhibit cell adhesion

Dec. 19, 2000

Merck Frosst synthesizes potent, selective and orally active PDE4 inhibitors

Dec. 18, 2000

Two series of inhibitors of alpha4beta1-mediated cell adhesion claimed by Aventis

Dec. 18, 2000

Nortran's phase II clinical trial of CP1 fails to meet primary endpoint

Dec. 18, 2000

Orally active HNE inhibitor in clinical trials at Ono

Dec. 18, 2000

Potent, long-acting, orally active M3 antagonist selected for clinical development at Banyu

Dec. 15, 2000

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 17, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 16, 2026
For clonal hematopoiesis, epigenetics can be in driver’s seat
BioWorld Science
Clonal hematopoiesis (CH), where few blood stem cells produce a significant fraction of mature blood cells that are genetically identical, is partly an inevitable...
Elixiron’s enrupatinib shows upbeat interim phase II AD results
BioWorld
Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant...
Gene replacement rescues autism-related phenotypes in mice
BioWorld Science
Autism spectrum disorder (ASD), developmental epileptic encephalopathies and other neurodevelopmental disorders are driven by the disruption of genes regulating...